BofA Securities initiated coverage on Madrigal Pharmaceuticals with a new price target
$MDGL
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities initiated coverage of Madrigal Pharmaceuticals with a rating of Underperform and set a new price target of $150.00